ArticleLiver cancer2019
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.
Masatoshi KudoPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this paperpooled itcites it